CLAIMS

1. Use of at least one of carbon dioxide or a pH adjusting material and fluticasone in an amount of 100 μg, 200 μg,or 400 μg in the preparation of a medicament for treating nasal polyps in a patient, wherein said fluticasone is to be administered before, after, before and after, or at the same time as said carbon dioxide or pH adjusting material, and wherein said carbon dioxide or pH adjusting material is to be delivered to a location at an interior of a nasal passage of said patient and to adjust a pH in said nasal passage location by an amount ranging from about 0.01 pH units to about 0.5 pH units.

2. The use of claim 1, wherein said fluticasone is to be administered before said carbon dioxide or pH adjusting material is delivered.

3. The use of claim 1, wherein said fluticasone is to be administered after said carbon dioxide or pH adjusting material is delivered.

4. The use of claim 1, wherein said carbon dioxide or pH adjusting material is to be delivered both before and after said fluticasone is administered or at the same time as said fluticasone is administered.

5. The use of claim 1, wherein said nasal passage location includes an upper posterior region of said nasal passage.

6. The use of claim 1, wherein said fluticasone is in the form of fluticasone propionate.

7. The use of claim 1, wherein said fluticasone is to be administered as a liquid aerosol.

8. The use of claim 1, wherein said fluticasone, when intranasally administered has a systemic bioavailability or pharmacokinetic (PK) profile which is equivalent to or not greater than the systemic bioavailability of 50 μg of said fluticasone when intranasally administered without said carbon dioxide or pH adjusting material.

9. The use of claim 1, wherein said amount ranges from about 0.1 pH units to about 0.2 pH units.

10. The use of claim 1, wherein said carbon dioxide is to be delivered in a concentration of from about 1% vol/vol to about 10% vol/vol carbon dioxide.

11. The use of claim 10, wherein said concentration of carbon dioxide is from about 5% vol/vol to about 6% vol/vol carbon dioxide.

12. The use of claim 1, wherein said carbon dioxide or pH adjusting material is to be delivered by placing a mouthpiece into a mouth of said patient and a nosepiece into a nostril of said patient;

said patient exhaling a breath into said mouthpiece to create a fluid flow out of said nosepiece, and

directing said fluid flow to said nasal passage location.

13. The use of claim 12, wherein said pH at said nasal passage location is adjusted by controlling said fluid flow.

14. The use of claim 13, wherein said fluid flow is controlled by controlling at least one of a duration, a rate, a pressure, and a composition of said fluid flow.

15. The use of claim 14, wherein said fluid flow duration is controlled to be in a range of from about 2s to about 3 s.

16. The use of claim 15, wherein said fluid flow rate is controlled to be at least 10 L/min, or at least 20 L/min.

17. The use of claim 12, wherein said carbon dioxide or pH adjusting material is further delivered by:

placing said nosepiece into a second nostril of said patient,

said patient exhaling a breath into said mouthpiece to create a second fluid flow out of said nosepiece, and

directing said second fluid flow to a second location within a second nasal passage.